- Home
- KBSX vs XFOR Comparison
KBSX vs XFOR Comparison
Compare KBSX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBSX
- XFOR
- Stock Information
- Founded
- KBSX N/A
- XFOR 2014
- Country
- KBSX Taiwan
- XFOR United States
- Employees
- KBSX N/A
- XFOR N/A
- Industry
- KBSX Recreational Games/Products/Toys
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KBSX Consumer Discretionary
- XFOR Health Care
- Exchange
- KBSX Nasdaq
- XFOR Nasdaq
- Market Cap
- KBSX 104.0M
- XFOR 118.4M
- IPO Year
- KBSX N/A
- XFOR N/A
- Fundamental
- Price
- KBSX N/A
- XFOR $0.51
- Analyst Decision
- KBSX
- XFOR Strong Buy
- Analyst Count
- KBSX 0
- XFOR 3
- Target Price
- KBSX N/A
- XFOR $3.50
- AVG Volume (30 Days)
- KBSX N/A
- XFOR 2.9M
- Earning Date
- KBSX N/A
- XFOR 11-13-2024
- Dividend Yield
- KBSX N/A
- XFOR N/A
- EPS Growth
- KBSX N/A
- XFOR N/A
- EPS
- KBSX N/A
- XFOR N/A
- Revenue
- KBSX N/A
- XFOR $1,123,000.00
- Revenue This Year
- KBSX N/A
- XFOR N/A
- Revenue Next Year
- KBSX N/A
- XFOR $652.72
- P/E Ratio
- KBSX N/A
- XFOR N/A
- Revenue Growth
- KBSX N/A
- XFOR N/A
- 52 Week Low
- KBSX N/A
- XFOR $0.26
- 52 Week High
- KBSX N/A
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- KBSX N/A
- XFOR 42.67
- Support Level
- KBSX N/A
- XFOR $0.43
- Resistance Level
- KBSX N/A
- XFOR $0.89
- Average True Range (ATR)
- KBSX 0.00
- XFOR 0.09
- MACD
- KBSX 0.00
- XFOR -0.04
- Stochastic Oscillator
- KBSX 0.00
- XFOR 17.61
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.